0001209191-22-049820.txt : 20220914 0001209191-22-049820.hdr.sgml : 20220914 20220914080013 ACCESSION NUMBER: 0001209191-22-049820 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220913 FILED AS OF DATE: 20220914 DATE AS OF CHANGE: 20220914 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Chambers Michael Andrew CENTRAL INDEX KEY: 0001932527 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14895 FILM NUMBER: 221242090 MAIL ADDRESS: STREET 1: 215 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc. CENTRAL INDEX KEY: 0000873303 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 930797222 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-274-4000 MAIL ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Sarepta Therapuetics, Inc. DATE OF NAME CHANGE: 20120712 FORMER COMPANY: FORMER CONFORMED NAME: AVI BIOPHARMA INC DATE OF NAME CHANGE: 19980930 FORMER COMPANY: FORMER CONFORMED NAME: ANTIVIRALS INC DATE OF NAME CHANGE: 19970123 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-09-13 0 0000873303 Sarepta Therapeutics, Inc. SRPT 0001932527 Chambers Michael Andrew 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142 1 0 0 0 Convertible Senior Notes 141.97 2022-09-13 4 A 0 20000000.00 20000000.00 A Common Stock 140879 20000000.00 I By Revocable Trust On September 13, 2022, the Reporting Person and the Company entered into a purchase agreement related to a purchase by the Reporting Person of $20,000,000 in aggregate principal amount of the Company's 1.25% Convertible Senior Notes due 2027 (the "2027 Notes") in a private placement from the Company. The private placement is expected to close on September 16, 2022, subject to customary closing conditions. The 2027 Notes are convertible at the election of the holder at any time prior to the close of business on the business day immediately preceding March 15, 2027, provided that certain convertibility conditions are met. On or after March 15, 2027 until the close of business on the second scheduled trading day immediately preceding the maturity date (September 15, 2027), holders may convert their notes at any time, regardless of the foregoing circumstances. Any conversion of the 2027 Notes may be settled in shares of Common Stock, cash or a combination of cash and shares of Common Stock at the Company's election. /s/ Ryan Brown, as Attorney-in-Fact for Michael Andrew Chambers 2022-09-14